The Diagnostic Value of APTT/Fibrinogen Ratio in Pulmonary Embolism

Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Jan 3, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help diagnose pulmonary embolism, a serious condition where one or more blood clots block the arteries in the lungs. The researchers are looking at a specific test called the APTT/fibrinogen ratio, which could provide important information about a patient's risk for this condition. The trial will take place at Nanyang Hospital from January to December 2023 and will involve patients who are suspected of having a pulmonary embolism and have undergone a special scan of their lungs.

To participate, individuals must be at least 18 years old and willing to provide consent. They should have been diagnosed with suspected pulmonary embolism and received a lung scan during the study period. However, those with certain serious health issues, like bleeding disorders or severe heart problems, will not be eligible. Participants will have their test results tracked over time, especially after they receive treatment to see how their APTT/fibrinogen ratio changes. This trial could help improve the way doctors diagnose and treat pulmonary embolism, ultimately aiming to enhance patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntary signing of informed consent form;
• • 2. When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender;
• • 3. From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination.
• Exclusion Criteria:
• • 1. Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction;
• • 2. Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation;
• • 3. Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement;
• • 4. Patients deemed unsuitable for participation in this study by the researchers.